Merck & Co has agreed to pay rival Bristol-Myers Squibb $625 million, plus royalties, to settle a patent case relating to the companies' rival cancer immunotherapies. Merck’s Keytruda ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Merck & Co.’s Keytruda is the world’s best ... which is a lot of weight to bear for a tentpole drug teetering on the edge of a patent cliff. That’s why the pharma giant is boosting the ...

The US patent ... that have deferred their launch plans for generics until May or July 2026 depending on the formulation, "or earlier under certain circumstances," according to a Merck statement.

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on. In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.